Kaituo Pharmaceuticals -B (09939.HK): KT-939 human long-term safety trial has completed all subjects enrollment.

Intelligence Financial APP News, Kotra Pharmaceutical-B (09939.HK) announced that the human long-term safety trial of the self-developed novel high-efficiency tyrosinase inhibitor KT-939, which inhibits the generation of melanin, has recently been completed with all 130 subjects enrolled. KT-939 can accurately target tyrosinase, efficiently block the oxidation process of tyrosine, effectively inhibit melanin production, and also has anti-oxidant and anti-inflammatory effects, demonstrating outstanding advantages in the efficacy, activity, and safety of cosmetics.